MBNL1 regulates essential alternative RNA splicing patterns in MLL-rearranged leukemia. Nature Communications. 2020; 11(1):2369.
High-risk LCH in infants is serially transplantable in a xenograft model but responds durably to targeted therapy. Blood advances. 2020; 4(4):717-727.
Real-time genomic profiling of histiocytoses identifies early-kinase domain BRAF alterations while improving treatment outcomes. JCI Insight. 2017; 2(3):e89473.
CPX-351 in High-Risk Relapsed Pediatric Acute Leukemia: Real-World Phase 1 Data Establishing the FDA-Approved Dose. Pediatric Blood and Cancer. 2026; 73(6):e70268.
Scaffolding-dependent CASP1 constrains excessive cell-intrinsic inflammatory signaling in leukemia. Cell Chemical Biology. 2026; 33(1):59-73.e10.
RNA helicase DDX3X promotes NK cell survival by supporting MCL1 expression. Journal of Immunology. 2025; 214(12):3218-3227.
Clinical outcomes of hypomethylating agents and venetoclax in newly diagnosed unfit and relapsed/refractory paediatric, adolescent and young adult acute myeloid leukaemia patients. British Journal of Haematology. 2024; 205(3):1055-1066.
LAMP-5 is an essential inflammatory-signaling regulator and novel immunotherapy target for mixed lineage leukemia-rearranged acute leukemia. Haematologica. 2022; 107(4):803-815.
TRAF6 functions as a tumor suppressor in myeloid malignancies by directly targeting MYC oncogenic activity. Cell Stem Cell. 2022; 29(2):298-314.e9.
An In Vivo CRISPR Screening Platform for Prioritizing Therapeutic Targets in AML. Cancer Discovery. 2022; 12(2):432-449.
An In Vivo CRISPR Screening Platform to Identify New Therapeutic Targets in AML. Blood. 2021; 138(Supplement 1):266.
Treatment of posttransplant lymphoproliferative disorder with poor prognostic features in children and young adults: Short-course EPOCH regimens are safe and effective. Pediatric Blood and Cancer. 2021; 68(8):e29126.